ProKidney is developing rilparencel, a first-in-class cell therapy aimed at preserving kidney function in patients with advanced chronic kidney disease (CKD). This therapy addresses the critical need for effective treatment options to delay or eliminate the progression to dialysis for patients facing limited alternatives.
Funding
Funding not disclosed
Founders
Product
Problem
Advanced chronic kidney disease (CKD) affects millions, with a significant number progressing to dialysis each year. Current treatments can slow the progression of CKD, but therapeutic options to delay the need for dialysis in patients with Stage 4 CKD are limited. Management of these patients primarily focuses on addressing comorbidities and preparing them for dialysis.
Solution
ProKidney is developing rilparencel, a first-in-class cell therapy, to address the unmet need for effective treatments for advanced CKD. Rilparencel aims to preserve kidney function in patients, potentially delaying or eliminating the need for dialysis. Early clinical data suggests that rilparencel has the potential to disrupt the CKD treatment landscape by offering a new approach focused on preserving kidney function.
Target Audience
The primary target audience includes patients with advanced chronic kidney disease (CKD) and the healthcare providers who manage their care, specifically those in Stage 4 CKD with limited therapeutic options.
Features
- First-in-class cell therapy candidate
- Aims to preserve kidney function in patients with advanced CKD
- Designed to potentially delay or eliminate the need for dialysis